First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt).

被引：65

作者：

Siefker-Radtke, Arlene O.

Necchi, Andrea

Park, Se Hoon

GarcAa-Donas, JesAs

Huddart, Robert A.

Burgess, Earle Frederick

Fleming, Mark T.

Rezazadeh, Arash

Mellado, Begona

Varlamov, Sergei

Joshi, Monika

Duran, Ignacio

Tagawa, Scott T.

OHagan, Anne

Avadhani, Anjali Narayan

Zhong, Bob

De Porre, Peter

Loriot, Yohann

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[2] Ist Nazl Tumori, Milan, Italy

[3] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea

[4] Clara Campal Comprehens Canc Ctr CIOCC, Madrid, Spain

[5] Inst Canc Res, Sutton, Surrey, England

[6] Carolinas HealthCare Syst, Levine Canc Inst, Charlotte, NC USA

[7] US Oncol Res, Virginia Oncol Associates, Norfolk, VA USA

[8] Norton Healthcare, Louisville, KY USA

[9] Inst Investigac Biomed August Pi Sunyer IDIBAPS, Barcelona, Spain

[10] Altai Reg Canc Ctr, Barnaul, Russia

[11] Penn State Canc Inst, Hershey, PA USA

[12] Hosp Univ Marques Valdecilla, Santander, Spain

[13] Weill Cornell Med Coll, Div Hematol Med Oncol, Dept Urol, Meyer Canc Ctr, New York, NY USA

[14] New York Presbyterian Hosp, New York, NY USA

[15] Janssen Res & Dev, Spring House, PA USA

[16] Janssen Res & Dev, Beerse, Belgium

[17] Inst Gustave Roussy, Villejuif, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.4503

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4503

引用

页数：2

共 50 条

[21] Erdafitinib (ERDA) in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC): Subgroup analyses of long-term efficacy outcomes of a pivotal phase II trial (BLC2001)
Necchi, A.
Siefker-Radtke, A. O.
Loriot, Y.
Park, S. H.
Garcia-Donas, J.
Huddart, R. A.
Burgess, E. F.
Fleming, M. T.
Rezazadeh, A.
Mellado, B.
Varlamov, S.
Joshi, M.
Duran, I.
Zakharia, Y.
Fu, M.
Santiago-Walker, A.
O'Hagan, A.
Monga, M.
Tagawa, S. T.
ANNALS OF ONCOLOGY, 2020, 31 : S583 - S583
[22] Second or Third Line Therapy of unresectable or metastatic Urothelial Carcinoma Phase 3 Study of Erdafitinib versus Vinflunine or Docetaxel or Pembrolizumab in Patients with advanced Urothelial Carcinoma and Alterations in the FGFR Genes. (THOR) - AB 79/21 of the AUO
Rexer, H.
Peters, I.
Retz, M.
UROLOGIE, 2022, 61 (08): : 915 - 916
[23] Atezolizumab in patients (pts) with locally-advanced or metastatic urothelial carcinoma (mUC): Results from a pivotal multicenter phase II study (IMvigor 210)
Rosenberg, J.
Petrylak, D.
Abidoye, O.
Van der Heijden, M. S.
Hofman-Censits, J.
Necchi, A.
O'Donnell, P. H.
Balmanoukian, A.
Loriot, Y.
Retz, M.
Perez-Gracia, J. L.
Dawson, N. A.
Balar, A.
Galsky, M. D.
Fleming, M. T.
Powles, T.
Cui, N.
Mariathasan, S.
Fine, G. D.
Dreicer, R.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S720 - S720
[24] ATLAS: A phase 2, open-label study of rucaparib in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC).
Grivas, Petros
Nepert, Dale L.
Wride, Kenton
Thomas, Daleen
Loehr, Andrea
Simmons, Andrew
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[25] Phase II study of futibatinib plus pembrolizumab in patients (pts) with advanced/metastatic urothelial carcinoma (mUC): Final analysis of efficacy and safety
Koshkin, V. S.
Barthelemy, P.
Gravis, G.
Goodman, O.
Duran, I.
Girones Sarrio, R.
Hwang, C.
Garcia-Donas, J.
Morales Barrera, R.
Zanetta, S.
Chisamore, M.
Liu, M.
Gil, M.
Tomlinson, G.
Elsayed, H.
Loriot, Y.
ANNALS OF ONCOLOGY, 2024, 35 : S1136 - S1137
[26] MSK-ACCESS for the detection of fibroblast growth factor receptor-3 (FGFR3) mutations in plasma cell-free (cf)DNA of metastatic urothelial carcinoma (mUC) patients (pts) pre- and on erdafitinib (erda) therapy.
Sarfaty, Michal
Teo, Min Yuen
Funt, Samuel Aaron
Lee, Chung-Han
Aggen, David Henry
Ratna, Neha
Regazzi, Ashley Marie
Al-Ahmadie, Hikmat
Brannon, Angela Rose
Berger, Michael F.
Solit, David B.
Rosenberg, Jonathan E.
Bajorin, Dean F.
Iyer, Gopa
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[27] Phase Ib trial of erdafitinib (E) combined with enfortumab vedotin (EV) following platinum and PD-1/L1 inhibitors for metastatic urothelial carcinoma (mUC) with FGFR2/3 genetic alterations (GAs).
Jain, Rohit K.
Kim, Youngchul
Rembisz, Jennifer
Piekarz, Richard
Synold, Timothy W.
Zhang, Jingsong
Sonpavde, Guru P.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
[28] Phase Ib trial of erdafitinib (E) combined with enfortumab vedotin (EV) following platinum and PD-1/L1 inhibitors for metastatic urothelial carcinoma (mUC) with FGFR2/3 genetic alterations (GAs).
Jain, Rohit K.
Heiligh, Jazlyn
Kim, Youngchul
Piekarz, Richard
Pelosof, Lorraine Cheryl
Yang, Yuanquan
D'souza, Anishka
Wong, Risa Liang
Graham, Laura
Gupta, Sumati
Park, Anna
Synold, Timothy W.
Sonpavde, Guru P.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 625 - 625
[29] Atezolizumab (atezo) in patients with metastatic urothelial carcinoma (mUC): A 2-year clinical update from a phase Ia study.
Petrylak, Daniel Peter
Powles, Thomas
Bellmunt, Joaquim
Braiteh, Fadi S.
Loriot, Yohann
Morales, Rafael
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
[30] Updated analysis with longer follow up of a phase 2a study evaluating erdafitinib in Asian patients (pts) with advanced cholangiocarcinoma (CCA) and fibroblast growth factor receptor (FGFR) alterations
Feng, Yin-Hsun
Su, Wu-Chou
Oh, Do-Youn
Shen, Lin
Kim, Kyu-Pyo
Liu, Xiufeng
Liao, Huimin
Qing, Min
Qian, Jiaqi
Triantos, Spyros
Sweiti, Hussein
Park, Joon Oh
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)

← 1 2 3 4 5 →